Will VK2735 receive FDA Fast Track designation by 2025? | Categorical | | | 2 months ago | |
Will Viking Therapeutics start Phase 2 study of VK2735 by Dec 31, 2024? | Binary | | | 2 months ago | |
FDA approval status of VK2735 for obesity by end of 2025? | Categorical | | | 2 months ago | |
Viking Therapeutics stock price rises another 20% by end of 2024? | Binary | | | 2 months ago | |
Viking Therapeutics initiates Phase 2 study of oral VK2735 by end of 2024? | Binary | | | 2 months ago | |
Will Viking discuss VK2735 clinical path with FDA by Dec 31, 2024? | Binary | | | 2 months ago | |
Will VK2735 Phase 2 study report moderate/severe nausea? | Binary | | | 2 months ago | |
What weight loss will VK2735 Phase 2 study achieve? | Categorical | | | 2 months ago | |
Which company will Viking partner with for VK2735 by 2025? | Categorical | | | 2 months ago | |
VK2735 market share vs competitors by end of 2025? | Categorical | | | 2 months ago | |
Outcome of Phase 2 study of oral VK2735 by mid-2025? | Categorical | | | 2 months ago | |
Viking discusses VK2735 injectable with FDA by end of Q4 2024? | Binary | | | 2 months ago | |
